Potential for residual cardiovascular risk reduction: Eligibility for icosapent ethyl in the VERTIS CV population with type 2 diabetes and atherosclerotic cardiovascular disease

Overview

cited authors

Kim, Joseph M.; Bhatt, Deepak L.; Dagogo-Jack, Samuel; Cherney, David Z. I.; Cosentino, Francesco; McGuire, Darren K.; Pratley, Richard E.; Liu, Chih-Chin; Cater, Nilo B.; Frederich, Robert; Mancuso, James P.; Cannon, Christopher P.

authors

Pratley, Richard Edwin, MD

Publication Date

February 14, 2023

webpage

Web of Science

published in

DIABETES OBESITY & METABOLISM Journal

Research

keywords

REDUCE-IT
VERTIS CV
cardiovascular risk reduction
icosapent ethyl
type 2 diabetes

301 E Princeton St., Orlando, FL 32804 | FH.RAS@AdventHealth.com | 407-200-2901

The information on this website is not a substitute for examination, diagnosis, and medical care provided by a licensed and qualified health professional. Please consult your physician before undertaking any form of medical treatment and/or adopting any exercise program or dietary guidelines. If you think you may have a medical emergency, call your physician or 911 immediately. AdventHealth Research Institute reserves the right to add, remove or edit content on this page at its sole discretion.